A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction

International Journal of Cardiology

Volumn 167, Issue 4, 2013, Pages 1298-1304

  Xu, Dan Yan ^a   Davis, Benjamin B ^b   Wang, Zhen He ^a   Zhao, Shui Ping ^a   Wasti, Binaya ^a   Liu, Zhe Liang ^a   Li, Ning ^c   Morisseau, Christophe ^b   Chiamvimonvat, Nipavan ^c   Hammock, Bruce D ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myocardial infarction; Endothelial progenitor cells; Soluble epoxide hydrolase inhibitor; Vascular endothelial growth factor

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR RESPONSE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVASCULARIZATION;

ACUTE MYOCARDIAL INFARCTION; ENDOTHELIAL PROGENITOR CELLS; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR;

AGED; ANILIDES; BENZOATES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PPAR GAMMA; STEM CELLS; UREA;

EID: 84880735525     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.167     Document Type: Article

References (59)

1. A.H. Yin, S. Miraglia, E.D. Zanjani, G. Almeida-Porada, M. Ogawa, and A.G. Leary AC133, a novel marker for human hematopoietic stem and progenitor cells Blood 90 1997 5002 5012
2. H.S. Hung, W.C. Shyu, C.H. Tsai, S.H. Hsu, S.Z. Lin, and J. Tongers Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation Microvasc Res 79 3 2010 200 206
3. H.S. Hung, W.C. Shyu, C.H. Tsai, S.H. Hsu, and S.Z. Lin Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases Cell Transplant 18 9 2009 1003 1012
4. R.H. Ingraham, R.D. Gless, and H.Y. Lo Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions Curr Med Chem 18 4 2011 587 603
5. A.N. Simpkins, R.D. Rudic, S. Roy, H.J. Tsai, B.D. Hammock, and J.D. Imig Soluble epoxide hydrolase inhibition modulates vascular remodeling Am J Physiol Heart Circ Physiol 298 3 2010 H795 H806
6. L.N. Zhang, J. Vincelette, Y. Cheng, U. Mehra, D. Chen, and S.K. Anandan Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia Arterioscler Thromb Vasc Biol 29 9 2009 1265 1270
7. A.A. Spector, X. Fang, G.D. Snyder, and N.L. Weintraub Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function Prog Lipid Res 43 1 2004 55 90
8. D.C. Zeldin, J. Kobayashi, J.R. Falck, B.S. Winder, B.D. Hammock, and J.R. Snapper Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase J Biol Chem 268 9 1993 Mar 25 6402 6407
9. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol 292 3 2007 C996 C1012
10. J.W. Newman, C. Morisseau, and B.D. Hammock Epoxide hydrolases: their roles and interactions with lipid metabolism Prog Lipid Res 44 1 2005 1 51
11. A.W. Miller, C. Dimitropoulou, G. Han, R.E. White, D.W. Busija, and G.O. Carrier Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance Am J Physiol Heart Circ Physiol 281 2001 H1524 H1531
12. P. Luo, H.H. Chang, Y. Zhou, S. Zhang, S.H. Hwang, and C. Morisseau Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis J Pharmacol Exp Ther 334 2 2010 430 438
13. J. Bellien, R. Joannides, V. Richard, and C. Thuillez Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther 131 1 2011 Jul 1 17
14. N. Chiamvimonvat, C.M. Ho, H.J. Tsai, and B.D. Hammock The soluble epoxide hydrolase as a pharmaceutical target for hypertension J Cardiovasc Pharmacol 50 3 2007 225 237
15. A. Oguro, N. Fujita, and S. Imaoka Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression Drug Metab Pharmacokinet 24 5 2009 438 445
16. K.R. Chaudhary, M. Abukhashim, S.H. Hwang, B.D. Hammock, and J.M. Seubert Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido) -cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury J Cardiovasc Pharmacol 55 1 2010 67 73
17. H. Qiu, N. Li, J.Y. Liu, T.R. Harris, B.D. Hammock, and N. Chiamvimonvat Soluble epoxide hydrolase inhibitors and heart failure Cardiovasc Ther 2010 23
18. D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, and H.J. Tsai Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proc Natl Acad Sci U S A 103 49 2006 18733 18738
19. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat Rev Drug Discov 8 10 2009 794 805
20. N. Li, J.Y. Liu, V. Timofeyev, H. Qiu, S.H. Hwang, and D. Tuteja Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches J Mol Cell Cardiol 47 6 2009 835 845
21. S.H. Hwang, H.J. Tsai, J.Y. Liu, C. Morisseau, and B.D. Hammock Orally bioavailable potent soluble epoxide hydrolase inhibitors J Med Chem 50 16 2007 3825 3840
22. M.R. Schroeter, M. Leifheit, P. Sudholt, N.M. Heida, C. Dellas, and I. Rohm Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion Circ Res 103 5 2008 536 544
23. C. Qian, R.A. Tio, A.J. Roks, K.M. Boddeus, M.C. Harmsen, and W.H. van Gilst A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart Cardiovasc Pathol 16 3 2007 May-Jun 127 135
24. S. Rafii, and D. Lyden Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration Nat Med 9 6 2003 Jun 702 712
25. S. Dimmeler, A. Aicher, M. Vasa, C. Mildner-Rihm, K. Adler, and M. Tiemann MG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway J Clin Invest 108 3 2001 Aug 391 397
26. Y. Liu, Y. Zhang, K. Schmelzer, T.S. Lee, X. Fang, and Y. Zhu The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase Proc Natl Acad Sci U S A 102 46 2005 16747 16752
27. M. Lee, M. Aoki, T. Kondo, K. Kobayashi, K. Okumura, and K. Komori Therapeutic angiogenesis with intramuscular injection of low-dose recombinant granulocyte-colony stimulating factor Arterioscler Thromb Vasc Biol 25 12 2005 Dec 2535 2541
28. M.C. Cid, J. Hernández-Rodríguez, M.J. Esteban, M. Cebrián, Y.S. Gho, and C. Font Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis Circulation 106 13 2002 Sep 24 1664 1671
29. K. Jujo, M. Ii, and D.W. Losordo Endothelial progenitor cells in neovascularization of infarcted myocardium J Mol Cell Cardiol 45 4 2008 530 544
30. M. Albiero, L. Menegazzo, A. Avogaro, and G.P. Fadini Pharmacologic targeting of endothelial progenitor cells [J] Cardiovasc Hematol Disord Drug Targets 10 1 2010 16 32
31. N. Werner, S. Kosiol, T. Schiegl, P. Ahlers, K. Walenta, and A. Link Circulating endothelial progenitor cells and cardiovascular outcomes N Engl J Med 353 10 2005 Sep 8 999 1007
32. S. Li Calzi, M.B. Neu, L.C. Shaw, J.L. Kielczewski, N.I. Moldovan, and M.B. Grant EPCs and pathological angiogenesis: when good cells go bad Microvasc Res 79 3 2010 207 216
33. M. Hristov, and C. Weber Endothelial progenitor cells in vascular repair and remodeling Pharmacol Res 58 2 2008 148 151
34. A. Zampetaki, J.P. Kirton, and Q. Xu Vascular repair by endothelial progenitor cells Cardiovasc Res 78 3 2008 413 421
35. K.A. Jackson, S.M. Majka, H. Wang, J. Pocius, C.J. Hartley, and M.W. Majesky Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells J Clin Invest 107 2001 1395 1402
36. M. Gill, S. Dias, K. Hattori, M.L. Rivera, D. Hicklin, and L. Witte Vascular trauma induces rapid but transient mobilization of VEGFR2 + AC331 + endothelial precursor cells Circ Res 88 2001 167 174
37. S. Shintani, T. Murohara, H. Ikeda, T. Ueno, T. Honma, and A. Katoh Mobilization of endothelial progenitor cells in patients with acute myocardial infarction Circulation 103 2001 2776 2779
38. W. Wojakowiski, M. Tendera, A. Michalowska, M. Majka, M. Kucia, and K. Maslsnkiewicz Mobilization of CD34/CXCR4+, CD34/CD117+, c-met + stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction Circulation 110 2004 3213 3220
39. M. Massa, V. Rosti, M. Ferrario, R. Campanelli, I. Ramajoli, and R. Rosso Increased circulating hematopoietic and endothelial progenitorcells in the early phase of acute myocardial infarction Blood 105 2005 199 206
40. A. Liguori, C. Fiorito, M.L. Balestrieri, E. Crimi, G. Bruzzese, and S. Williams-Ignarro Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease Eur J Haematol 80 3 2008 258 264
41. C. Briguori, U. Testa, R. Riccioni, A. Colombo, E. Petrucci, and G. Condorelli Correlations between progression of coronary artery disease and circulating endothelial progenitor cells FASEB J 24 6 2010 1981 1988
42. M. Vasa, S. Fichtlscherer, A. Aicher, K. Adler, C. Urbich, and H. Martin Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease Circ Res 89 1 2001 Jul 6 E1 E7
43. L.T. Chang, C.M. Yuen, C.K. Sun, C.J. Wu, J.J. Sheu, and S. Chua Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty Circ J 73 6 2009 Jun 1097 1104
44. C. Baran, S. Durdu, K. Dalva, C. Zaim, A. Dogan, and G. Ocakoglu Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial Stem Cell Rev 8 3 2012 Sept 963 971
45. H.W. Chang, S. Leu, C.K. Sun, C.L. Hang, A.A. Youssef, and Y.K. Hsieh Level and value of circulating endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty: in vivo and in vitro studies Transl Res 156 4 2010 Oct 251 263
46. T.Q. Min, C.J. Zhu, W.X. Xiang, Z.J. Hui, and S.Y. Peng Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease Cardiovasc Drugs Ther 18 3 2004 May 203 209
47. T. Kito, R. Shibata, M. Kondo, T. Yamamoto, H. Suzuki, and M. Ishii Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice Am J Hypertens 25 4 2012 Apr 401 406
48. L. Dong, L. Kang, L. Ding, Q. Chen, J. Bai, and R. Gu Insulin modulates ischemia-induced endothelial progenitor cell mobilization and neovascularization in diabetic mice Microvasc Res 82 3 2011 Nov 227 236
49. J. Smythe, A. Fox, N. Fisher, E. Frith, A.L. Harris, and S.M. Watt Measuring angiogenic cytokines, circulating endothelial cells, and endothelial progenitor cells in peripheral blood and cord blood: VEGF and CXCL12 correlate with the number of circulating endothelial progenitor cells in peripheral blood Tissue Eng Part C Methods 14 1 2008 59 67
50. V.J. Dzau, M. Gnecchi, A.S. Pachori, F. Morello, and L.G. Melo Therapeutic potential of endothelial progenitor cells in cardiovascular diseases Hypertension 46 1 2005 Jul 7 18
51. D.W. Losordo, and S. Dimmeler Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies Circulation 109 22 2004 Jun 8 2692 2697
52. F. Mac Gabhann, A.A. Qutub, B.H. Annex, and A.S. Popel Systems biology of pro-angiogenic therapies targeting the VEGF system Wiley Interdiscip Rev Syst Biol Med 2 6 2010 Nov-Dec 694 707
53. J.X. Yu, X.F. Huang, W.M. Lv, C.S. Ye, X.Z. Peng, and H. Zhang Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization J Vasc Surg 50 3 2009 608 616
54. M. Jiang, B. Wang, C. Wang, B. He, H. Fan, and T.B. Guo Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs J Cell Biochem 103 1 2008 321 334
55. M.R. Hoenig, C. Bianchi, and F.W. Sellke Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis Curr Drug Targets 9 5 2008 422 435
56. K. Nithipatikom, and G.J. Gross Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection J Cardiovasc Pharmacol Ther 15 2 2010 112 119
57. A.A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J Lipid Res 50 Suppl. 2009 S52 S56
58. A.C. Webler, U.R. Michaelis, R. Popp, E. Barbosa-Sicard, A. Murugan, and J.R. Falck Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis Am J Physiol Cell Physiol 295 5 2008 C1292 C1301
59. D. Chen, R. Whitcomb, E. Macintyre, V. Tran, Z.N. Do, and J. Sabry Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects J Clin Pharmacol 52 3 2012 Mar 319 328